首页> 外文期刊>Nature >Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
【24h】

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

机译:全基因组测序可鉴定慢性淋巴细胞白血病的复发突变

获取原文
获取原文并翻译 | 示例
       

摘要

Chronic lymphocytic leukaemia (CLL), the most frequent leukaemia in adults in Western countries, is a heterogeneous disease with variable clinical presentation and evolution. Two major molecular subtypes can be distinguished, characterized respectively by a high or low number of somatic hypermutations in the variable region of immunoglobulin genes. The molecular changes leading to the pathogenesis of the disease are still poorly understood. Here we performed whole-genome sequencing of four cases of CLL and identified 46 somatic mutations that potentially affect gene function. Further analysis of these mutations in 363 patients with CLL identified four genes that are recurrently mutated: notch 1 (NOTCH1), exportin 1 (XPOl), myeloid differentiation primary response gene 88 (MYD88) and kelch-like 6 (KLHL6). Mutations in MYD88 and KLHL6 are predominant in cases of CLL with mutated immunoglobulin genes, whereas NOTCH1 and XPOl mutations are mainly detected in patients with unmutated irnmu-noglobulins. The patterns of somatic mutation, supported by functional and clinical analyses, strongly indicate that the recurrent NOTCH1, MYD88 and XPOl mutations are oncogenic changes that contribute to the clinical evolution of the disease. To our knowledge, this is the first comprehensive analysis of CLL combining whole-genome sequencing with clinical characteristics and clinical outcomes. It highlights the usefulness of this approach for the identification of clinically relevant mutations in cancer.
机译:慢性淋巴细胞性白血病(CLL)是西方国家成人中最常见的白血病,是一种异质性疾病,临床表现和进化过程均不相同。可以区分两种主要的分子亚型,分别以免疫球蛋白基因的可变区中的体细胞超突变的数量高或低为特征。导致疾病发病机理的分子变化仍然知之甚少。在这里,我们对4例CLL病例进行了全基因组测序,确定了46种可能影响基因功能的体细胞突变。在363名CLL患者中对这些突变进行了进一步分析,确定了四个经常突变的基因:缺口1(NOTCH1),出口蛋白1(XPO1),髓样分化主要反应基因88(MYD88)和kelch-like 6(KLHL6)。 MYD88和KLHL6突变在免疫球蛋白基因突变的CLL病例中占优势,而NOTCH1和XPO1突变主要在未突变的免疫球蛋白球蛋白患者中检测到。在功能和临床分析的支持下,体细胞突变的模式强烈表明,复发的NOTCH1,MYD88和XPO1突变是致癌性变化,有助于疾病的临床发展。据我们所知,这是将全基因组测序与临床特征和临床结果相结合的CLL的首次综合分析。它强调了这种方法对于鉴定临床上与癌症相关的突变的有用性。

著录项

  • 来源
    《Nature》 |2011年第7354期|p.101-105|共5页
  • 作者单位

    Departamento de Bioquimica y Biologia Molecular, Institute Universitariode Oncologia, Universidad de Oviedo, 33006 Oviedo, Spain;

    Unidad de Genomica, Institut d'lnvestigacions Biomediques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, Spain;

    Departamento de Bioquimica y Biologia Molecular, Institute Universitariode Oncologia, Universidad de Oviedo, 33006 Oviedo, Spain;

    Unidad de Hematopatologia, Servicio de Anatomia Patologica, Hospital Clinic, Universitat de Barcelona, IDIBAPS, 08036 Barcelona, Spain;

    Departamento de Bioquimica y Biologia Molecular, Institute Universitariode Oncologia, Universidad de Oviedo, 33006 Oviedo, Spain;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:54:39

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号